The Stealth Doctor covers retatrutide, the experimental weight loss drug still in trials and out of reach through normal prescriptions.
Recap by typeshit. Full story at The Stealth Doctor.
A short item claims a newer group of weight loss drugs beats Ozempic, without naming the drugs or the data behind the claim.
The digital health doctor shares a take on GLP-1 therapy paired with lifestyle change and digital programs, calling the finding unsurprising.
The obesity medicine specialist told a Fall Clinical 2026 panel that sleep apnea, MASH and heart coverage can open GLP-1 access, and that retatrutide could reach market next year.
In a 12-week study of 245 adults, Omada reports its members cut body fat percentage about twice as much as usual care. Results go to WOC 2026 in Boston.
A listing on Wegovy getting FDA approval as an obesity treatment, with no date or new details, so likely older news.
UW Medicine notes that many of these experimental peptides have not been regulated by the FDA, and some have never been tested in people.
Loading…